Associated Papers
The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis.
Thuy VT et al.
Leukemia Research, 2025
Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1.
Aly SM et al.
Forensic Science International. Genetics, 2025
Genetic Variants of SLC22A1 rs628031 and rs622342 and Glycemic Control in T2DM Patients from Northern Mexico.
Moreno-González JG et al.
Genes, 2025
Insights Into Genetic Variations of the OCT1 Gene in Metformin Poor Responders Among Bangladeshi Type 2 Diabetic Patients.
Begum R et al.
Advances in Pharmacological and Pharmaceutical Sciences, 2025
Metformin efficacy and tolerance according to genetic polymorphisms of organic cation transporter 1 in Tunisian patients with type 2 diabetes.
Chaker F et al.
Frontiers in Endocrinology, 2025
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Staropoli N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG et al.
Cancer Drug Resistance (alhambra, Calif.), 2024
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
He S et al.
Cancer Chemotherapy and Pharmacology, 2023
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.
Yee SW et al.
Biorxiv : the Preprint Server for Biology, 2023
Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.
Singh S et al.
Pharmacogenetics and Genomics, 2023
Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
Peng A et al.
Frontiers in Public Health, 2023
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.
Nies AT et al.
Pharmacology & Therapeutics, 2022
Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.
Alves R et al.
International Journal of Molecular Sciences, 2022
Variants of SLC2A10 may be Linked to Poor Response to Metformin.
Paz-Pacheco E et al.
Journal of the Endocrine Society, 2022
Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus.
Nasykhova YA et al.
Genes, 2022
Role of human organic cation transporter-1 (OCT-1/SLC22A1) in modulating the response to metformin in patients with type 2 diabetes.
Kawoosa F et al.
Bmc Endocrine Disorders, 2022
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.
Dagli-Hernandez C et al.
Pharmaceutics, 2022
Genetic variants in SLC22A1 are related to serum lipid levels in Mexican women.
Cahua-Pablo JÁ et al.
Lipids, 2022
Pharmacogenetics of Drugs Used in the Treatment of Cancers.
Franczyk B et al.
Genes, 2022
Effect of Metformin on Glycemic Control Regarding Carriers of the SLC22A1/OCT1 (rs628031) Polymorphism and Its Interactions with Dietary Micronutrients in Type 2 Diabetes.
Zepeda-Carrillo EA et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.
Mohammadi F et al.
Laboratory Medicine, 2021
Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.
Wang ML et al.
Pharmacological Research, 2021
Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment.
Pernaute-Lau L et al.
Antimicrobial Agents and Chemotherapy, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Diabetes and Genetics: A Relationship Between Genetic Risk Alleles, Clinical Phenotypes and Therapeutic Approaches.
Sayed S et al.
Advances in Experimental Medicine and Biology, 2021
Effects of a Common Eight Base Pairs Duplication at the Exon 7-Intron 7 Junction on Splicing, Expression, and Function of OCT1.
Römer S et al.
Frontiers in Pharmacology, 2021
Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.
Rajamani BM et al.
Scientific Reports, 2020
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis.
Yumiceba V et al.
Frontiers in Endocrinology, 2020
The genetic landscape of the human solute carrier (SLC) transporter superfamily.
Schaller L et al.
Human Genetics, 2019
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review.
Kulma I et al.
Cancer Chemotherapy and Pharmacology, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Association between Polymorphisms of OCT1 and Metabolic Response to Metformin in Women with Polycystic Ovary Syndrome.
Chang HH et al.
International Journal of Molecular Sciences, 2019
Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy.
Wang ZZ et al.
Frontiers in Pharmacology, 2019
SLC22A1 And ATM Genes Polymorphisms Are Associated With The Risk Of Type 2 Diabetes Mellitus In Western Saudi Arabia: A Case-Control Study.
Altall RM et al.
The Application of Clinical Genetics, 2019
Use of Germline Genetic Variability for Prediction of Chemoresistance and Prognosis of Breast Cancer Patients.
Hlavac V et al.
Cancers, 2018
Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants.
van Groen BD et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2018
The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients.
Belohlavkova P et al.
Archives of Medical Science : Ams, 2018
Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP et al.
Medicine, 2018
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
Cargnin S et al.
Pharmacological Research, 2018
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.
Lozano E et al.
Journal of Personalized Medicine, 2018
Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content.
Liang X et al.
Plos Biology, 2018
Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport.
Kim HI et al.
American Journal of Human Genetics, 2017
hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I et al.
Cancer Chemotherapy and Pharmacology, 2017